Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(157 produtos)
- Bcr-Abl(113 produtos)
- EGFR(596 produtos)
- FAK(72 produtos)
- FLT(88 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(180 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2002 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK/PI3K/AKT-IN-1
CAS:ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.Fórmula:C25H20FN5O2SCor e Forma:SolidPeso molecular:473.522FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Fórmula:C28H31ClN8O3Cor e Forma:SolidPeso molecular:563.05HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Fórmula:C26H32N8O3Cor e Forma:SolidPeso molecular:504.58Tofacitinib Prodrug-1
Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.Fórmula:C36H39ClN10O7Cor e Forma:SolidPeso molecular:759.21SILA-123
CAS:<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Fórmula:C24H25N5O2Cor e Forma:SolidPeso molecular:415.49EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Fórmula:C26H27ClN6O2Cor e Forma:SolidPeso molecular:490.98Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Fórmula:C26H26N6O2Cor e Forma:SolidPeso molecular:454.52CLM3
CAS:<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Fórmula:C21H21N5Cor e Forma:SolidPeso molecular:343.43FAK-IN-26
CAS:<p>FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.</p>Fórmula:C20H19BrFN5O2Cor e Forma:SolidPeso molecular:460.30ERBB agonist-1
CAS:ERBB agonist-1 (Compound EF-1) is an ERBB4 agonist that activates the ERBB4 signaling pathway by inducing ERBB4 receptor dimerization, with an EC50 of 10.5 μM. It promotes phosphorylation of Akt and ERK1/2, reduces collagen expression in cardiac fibroblasts, and inhibits H2O2-induced cardiomyocyte death and Ang II-induced cardiac hypertrophy. Furthermore, ERBB agonist-1 can prevent myocardial fibrosis and demonstrates cardioprotective effects in mouse models.Fórmula:C24H25N3O2SCor e Forma:SolidPeso molecular:419.539Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Fórmula:C32H31ClN6O4Cor e Forma:SolidPeso molecular:599.08SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Fórmula:C27H26ClF4N5OCor e Forma:SolidPeso molecular:547.98LT-850-166
LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.Fórmula:C30H29Cl2N7OCor e Forma:SolidPeso molecular:574.5CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Fórmula:C32H30N6O3Cor e Forma:SolidPeso molecular:546.619VEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Fórmula:C29H22BrN5SCor e Forma:SolidPeso molecular:552.49BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Fórmula:C18H15N3O2Cor e Forma:SolidPeso molecular:305.331I194496
CAS:<p>I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.</p>Fórmula:C28H23F2N5O5SCor e Forma:SolidPeso molecular:579.58HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Fórmula:C19H14BrF3N2OCor e Forma:SolidPeso molecular:423.23HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Fórmula:C26H25F2N9O3Cor e Forma:SolidPeso molecular:549.53Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Fórmula:C19H20FN5OSCor e Forma:SolidPeso molecular:385.458
